title: CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
abstract: OBJECTIVE
  Chemoradiotherapy has been considered standard treatment for patients with limited-stage aggressive lymphoma on the basis of trials conducted before the introduction of the International Prognostic Index. To evaluate this approach in elderly patients with low-risk localized lymphoma, we conducted a trial comparing chemoradiotherapy with chemotherapy alone.
  
  
  METHODS
  Previously untreated patients older than 60 years with localized stage I or II histologically aggressive lymphoma and no adverse prognostic factors of the International Prognostic Index were randomly assigned to receive either four cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus involved-field radiotherapy (299 patients) or chemotherapy alone with four cycles of CHOP (277 patients).
  
  
  RESULTS
  With a median follow-up time of 7 years, event-free and overall survival did not differ between the two treatment groups (P = .6 and P = .5, respectively). The 5-year estimates of event-free survival were 61% for patients receiving chemotherapy alone and 64% for patients receiving CHOP plus radiotherapy; the 5-year estimates of overall survival were 72% and 68%, respectively. In a multivariate analysis, overall survival was affected by stage II disease (P < .001) and male sex (P = .03).
  
  
  CONCLUSIONS
  In this large prospective study, CHOP plus radiotherapy did not provide any advantage over CHOP alone for the treatment of low-risk localized aggressive lymphoma in elderly patients.
authors.affiliation: Centre Hospitalier Universitaire, Université de Liège, Liège, Belgium.
authors.forename: Christophe
authors.initials: C
authors.lastname: Bonnet
authors.forename: Georges
authors.initials: G
authors.lastname: Fillet
authors.forename: Nicolas
authors.initials: N
authors.lastname: Mounier
authors.forename: Gérard
authors.initials: G
authors.lastname: Ganem
authors.forename: Thierry Jo
authors.initials: TJ
authors.lastname: Molina
authors.forename: Catherine
authors.initials: C
authors.lastname: Thiéblemont
authors.forename: Christophe
authors.initials: C
authors.lastname: Fermé
authors.forename: Bruno
authors.initials: B
authors.lastname: Quesnel
authors.forename: Claude
authors.initials: C
authors.lastname: Martin
authors.forename: Christian
authors.initials: C
authors.lastname: Gisselbrecht
authors.forename: Hervé
authors.initials: H
authors.lastname: Tilly
authors.forename: Félix
authors.initials: F
authors.lastname: Reyes
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone